Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-tocopheryl phosphate (TP) is a phosphorylated derivative of alpha-tocopherol (Vitamin E) that occurs naturally in biological tissues and plasma. Unlike its non-phosphorylated counterpart, TP acts as a potent signaling molecule rather than just a lipid-soluble antioxidant. It has been shown to inhibit cell proliferation in smooth muscle cells and monocytes, modulate the expression of genes involved in lipid uptake such as CD36, and inhibit protein kinase C (PKC) activity. Developed primarily by Phosphagenics (now part of Starpharma's legacy portfolio), it is often utilized in a proprietary mixture known as TPM (Tocopheryl Phosphate Mixture) to enhance the solubility and transdermal delivery of various drugs. Clinical and preclinical research has explored its potential in treating atherosclerosis, inflammation, and dermal conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-tocopheryl phosphate.